<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624958</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-232-01</org_study_id>
    <nct_id>NCT04624958</nct_id>
  </id_info>
  <brief_title>Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL</brief_title>
  <official_title>Zanubrutinib and Rituximab Followed by R-DHAOx (Rituximab, Dexamethasone, Cytarabine and Oxaliplatin) Regimen Then Maintenance With Zanubrutinib for Newly-Diagnosed Mantle Cell Lymphoma (MCL): a Single Arm, Open Label, Multi-center Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 trial studies the efficacy and safety of zanubrutinib plus rituximab followed by&#xD;
      R-DHAOx (rituximab, dexamethasone, cytarabine and oxaliplatin) regimen then maintenance with&#xD;
      zanubrutinib for newly-diagnosed Mantle Cell Lymphoma (MCL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate after PART A</measure>
    <time_frame>3 years</time_frame>
    <description>Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate after study treatment</measure>
    <time_frame>3 years</time_frame>
    <description>Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response rate</measure>
    <time_frame>3 years</time_frame>
    <description>Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the start of treatment to the progression of the tumor or death (due to any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the start of treatment to time of death (due to any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>3 years</time_frame>
    <description>The time from the start of treatment to the first assessment of complete remission or partial remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>3 years</time_frame>
    <description>Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Newly-diagnosed Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>zanubrutinib, rituximab, consolidation chemotherapy and zanubrutinb maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A (Zanubrutinib and Rituximab): Patients receive zanubrutinib on days 1-28 and rituximab on day 1. Treatment cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve CR.&#xD;
PART B (Consolidation chemotherapy of R-DHAOx): Patients receive R-DHAOx regimen every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Elderly patients (&gt; 65 years old) and patients who achieved CR and minimal residual disease negative after PART B receive zanubrutinb maintenance therapy. Young patients (&lt;65 years old) who achieved CR but minimal residual disease positive after PART B can receive autologous stem cell transplantation and then zanubrutinb maintenance therapy. Patients with PD, SD or PR after PART B quit the trial.&#xD;
ZANUBRUTINB MAINTENANCE: Patients receive zanubrutinib every day for up to one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib and Rituximab</intervention_name>
    <description>Zanubrutinb 160mg PO BID d1-28; Rituximab 375mg/m2 iv.drip d1.</description>
    <arm_group_label>zanubrutinib, rituximab, consolidation chemotherapy and zanubrutinb maintenance</arm_group_label>
    <other_name>PART A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-DHAOx</intervention_name>
    <description>Rituximab 375mg/m2 iv.drip d1; Dexamethasone 20mg iv.drip d1-4; Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3 Oxaliplatin 130mg/m2 iv.drip d1.</description>
    <arm_group_label>zanubrutinib, rituximab, consolidation chemotherapy and zanubrutinb maintenance</arm_group_label>
    <other_name>PART B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib Maintenance</intervention_name>
    <description>Zanubrutinb 160mg PO BID.</description>
    <arm_group_label>zanubrutinib, rituximab, consolidation chemotherapy and zanubrutinb maintenance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed CD20 positive mantle cell lymphoma;&#xD;
&#xD;
          -  Patients with MCL-related symptomatic and need immediate therapy; Include any of the&#xD;
             following: (1) Blastoid variant (2) Pleomorphic variant (3) Ki-67 ≥30% (4) Bulky mass&#xD;
             &gt; 7 cm or ≥2 tumors, each ≥5 cm in diameter (5) Mutations in TP53, c-MYC or NOTCH&#xD;
             genes (6) Size of spleen ≥20 cm (7) Lymphoma B symptoms (8) Mantle Cell International&#xD;
             Prognostic Score (MIPI) &gt; 3 (9) Lymphoma threatening organ function (10) Elevated&#xD;
             lactate dehydrogenase (11) Peripheral blood white blood cell &gt; 50×10^9/L (12)&#xD;
             Pancytopenia due to bone marrow involvement (13) Pain due to lymphoma;&#xD;
&#xD;
          -  Patients received no prior anti-lymphoma treatment;&#xD;
&#xD;
          -  At least one evaluable lesion according to 2014 Lugano criteria;&#xD;
&#xD;
          -  Ann Arbor stage II-IV;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) of 0-2;&#xD;
&#xD;
          -  Life expectancy &gt; 3 months;&#xD;
&#xD;
          -  Able to participate in all required study procedures;&#xD;
&#xD;
          -  Proper functioning of the major organs: 1) The absolute value of neutrophils&#xD;
             (&gt;1.5×10^9/L); 2) platelet count (&gt; 75×10^9/L); 3) Hemoglobin (&gt; 80 g/L); 4) Serum&#xD;
             creatinine &lt;1.5 times Upper Limit Normal (ULN) ; 5) Serum total bilirubin &lt; 1.5 times&#xD;
             ULN; 6) Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) &lt; 2.5 times&#xD;
             ULN; 7) Coagulation function: International Normalized Ratio (INR), Prothrombin Time&#xD;
             (PT), Activated Partial Thromboplastin Time (APTT) &lt; 1.5 times ULN (unless the subject&#xD;
             is receiving anticoagulant therapy and PT and APTT are within the expected range at&#xD;
             screening time);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Involvement of central nervous system (CNS)&#xD;
&#xD;
          -  Patients with Hemophagocytic syndrome;&#xD;
&#xD;
          -  Patients with active bleeding, bleeding tendency or require anticoagulation treatment;&#xD;
&#xD;
          -  Patients require treatment with strong CYP3A inhibitors;&#xD;
&#xD;
          -  Uncontrolled active infection, with the exception of tumor-related B symptom fever;&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection and/or patients with acquired&#xD;
             immunodeficiency syndrome are known;&#xD;
&#xD;
          -  Patients with active hepatitis B or active hepatitis C. Patients who are positive for&#xD;
             hepatitis B Surface Antigen (HBsAg) or hepatitis C Virus (HCV) antibodies at screening&#xD;
             stage must pass further detection of hepatitis B Virus (HBV) DNA (no more than 1000&#xD;
             IU/mL) and HCV RNA (no more than the lower limit of the detection method) in the row.&#xD;
             Hepatitis B carriers, stable hepatitis B (DNA titer should not be higher than 1000&#xD;
             IU/mL) after drug treatment, and cured hepatitis C patients can be enrolled in the&#xD;
             group;&#xD;
&#xD;
          -  Diagnosed with or receiving treatment for malignancy other than lymphoma;&#xD;
&#xD;
          -  Pregnant or breastfeeding women;&#xD;
&#xD;
          -  Other researchers consider it unsuitable for patients to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingqing Cai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingqing Cai, MD</last_name>
    <phone>0086-20-87342823</phone>
    <email>caiqq@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenyu Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingqing Cai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueyi Pan, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Qingqing Cai</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

